Growth Hormone Disorders Completed Phase 3 Trials for Somatotropin (DB00052)

Also known as: Growth Hormone Disorder

IndicationStatusPhase
DBCOND0036845 (Growth Hormone Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03075644A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone DeficiencyTreatment
NCT02382939A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone DeficiencyTreatment
NCT02229851Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.Treatment
NCT01563926Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone DeficiencyTreatment
NCT01502124Safety and Efficacy of Somatropin in Children With Growth Hormone DeficiencyTreatment
NCT00519558Growth Hormone Deficiency in Adults (GHDA)Treatment
NCT00262249Effect of Growth Hormone in Children With Growth Hormone DeficiencyTreatment
NCT00184743Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)Treatment
NCT00184678Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone DeficiencyTreatment
NCT00184730Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)Treatment
NCT00102817Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient ChildrenTreatment